Parion Sciences
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
0%
0 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Role: lead
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Role: lead
Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
Role: lead
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
Role: lead
Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Role: lead
Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device
Role: collaborator
A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome
Role: lead
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Role: lead
A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device
Role: collaborator
Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Role: lead
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
Role: lead
All 11 trials loaded